ICON Public (NASDAQ:ICLR) Coverage Initiated at TD Cowen

Stock analysts at TD Cowen initiated coverage on shares of ICON Public (NASDAQ:ICLR) in a report issued on Wednesday, Briefing.com reports. The firm set an “outperform” rating and a $306.00 price target on the medical research company’s stock. TD Cowen’s target price indicates a potential upside of 16.89% from the stock’s current price.

Other analysts have also recently issued research reports about the company. StockNews.com assumed coverage on ICON Public in a research report on Thursday, August 17th. They set a “hold” rating for the company. Mizuho lifted their price target on ICON Public from $250.00 to $274.00 in a research report on Tuesday, July 11th. Barclays boosted their price objective on ICON Public from $250.00 to $280.00 and gave the company an “overweight” rating in a report on Friday, July 28th. Finally, Deutsche Bank Aktiengesellschaft boosted their price objective on ICON Public from $280.00 to $300.00 in a report on Friday, July 14th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $269.22.

ICON Public Stock Down 1.3 %

ICON Public stock opened at $261.78 on Wednesday. The stock has a market capitalization of $21.51 billion, a price-to-earnings ratio of 42.43, a PEG ratio of 1.48 and a beta of 1.12. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.22 and a quick ratio of 1.22. The business has a fifty day moving average price of $252.56 and a 200-day moving average price of $227.95. ICON Public has a 1-year low of $171.43 and a 1-year high of $268.07.

ICON Public (NASDAQ:ICLR) last issued its quarterly earnings results on Wednesday, July 26th. The medical research company reported $2.96 EPS for the quarter, topping analysts’ consensus estimates of $2.92 by $0.04. ICON Public had a return on equity of 11.21% and a net margin of 6.45%. The company had revenue of $2.02 billion during the quarter, compared to analysts’ expectations of $2.02 billion. Equities research analysts forecast that ICON Public will post 12.06 EPS for the current fiscal year.

Hedge Funds Weigh In On ICON Public

Large investors have recently bought and sold shares of the business. Motco increased its stake in ICON Public by 1,254.5% during the 2nd quarter. Motco now owns 149 shares of the medical research company’s stock worth $37,000 after buying an additional 138 shares in the last quarter. Farther Finance Advisors LLC increased its stake in ICON Public by 102.7% during the 2nd quarter. Farther Finance Advisors LLC now owns 150 shares of the medical research company’s stock worth $38,000 after buying an additional 76 shares in the last quarter. EverSource Wealth Advisors LLC increased its stake in ICON Public by 5,200.0% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 212 shares of the medical research company’s stock worth $53,000 after buying an additional 208 shares in the last quarter. First Horizon Advisors Inc. increased its stake in ICON Public by 10.0% during the 4th quarter. First Horizon Advisors Inc. now owns 497 shares of the medical research company’s stock worth $97,000 after buying an additional 45 shares in the last quarter. Finally, Alpha Paradigm Partners LLC purchased a new stake in ICON Public during the 3rd quarter worth approximately $123,000. Institutional investors and hedge funds own 95.21% of the company’s stock.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.